Drug-induced weight gain.

Rosane Ness-Abramof, Caroline M Apovian
{"title":"Drug-induced weight gain.","authors":"Rosane Ness-Abramof,&nbsp;Caroline M Apovian","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity. Improved glycemic control achieved by insulin, insulin secretagogues or thiazolidinedione therapy is generally accompanied by weight gain. It is a problematic side effect of therapy due to the known deleterious effect of weight gain on glucose control, increased blood pressure and worsening lipid profile. Weight gain may be lessened or prevented by adherence to diet and exercise or combination therapy with metformin. Weight gain is also common in psychotropic therapy. The atypical antipsychotic drugs (clozapine, olanzepine, risperidone and quetiapine) are known to cause marked weight gain. Antidepressants such as amitriptyline, mirtazapine and some serotonin reuptake inhibitors (SSRIs) also may promote appreciable weight gain that cannot be explained solely by improvement in depressive symptoms. The same phenomenon is observed with mood stabilizers such as lithium, valproic acid and carbamazepine. Antiepileptic drugs (AEDs) that promote weight gain include valproate, carbamazepine and gabapentin. Lamotrigine is an AED that is weight-neutral, while topiramate and zonisamide may induce weight loss.</p>","PeriodicalId":87159,"journal":{"name":"Timely topics in medicine. Cardiovascular diseases","volume":"9 ","pages":"E31"},"PeriodicalIF":0.0000,"publicationDate":"2005-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Timely topics in medicine. Cardiovascular diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity. Improved glycemic control achieved by insulin, insulin secretagogues or thiazolidinedione therapy is generally accompanied by weight gain. It is a problematic side effect of therapy due to the known deleterious effect of weight gain on glucose control, increased blood pressure and worsening lipid profile. Weight gain may be lessened or prevented by adherence to diet and exercise or combination therapy with metformin. Weight gain is also common in psychotropic therapy. The atypical antipsychotic drugs (clozapine, olanzepine, risperidone and quetiapine) are known to cause marked weight gain. Antidepressants such as amitriptyline, mirtazapine and some serotonin reuptake inhibitors (SSRIs) also may promote appreciable weight gain that cannot be explained solely by improvement in depressive symptoms. The same phenomenon is observed with mood stabilizers such as lithium, valproic acid and carbamazepine. Antiepileptic drugs (AEDs) that promote weight gain include valproate, carbamazepine and gabapentin. Lamotrigine is an AED that is weight-neutral, while topiramate and zonisamide may induce weight loss.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药物引起的体重增加。
药物引起的体重增加是许多常用药物的严重副作用,导致不遵守治疗并加剧与肥胖相关的合并症。通过胰岛素、胰岛素分泌剂或噻唑烷二酮治疗改善血糖控制通常伴随着体重增加。由于已知体重增加对血糖控制、血压升高和血脂恶化的有害影响,这是治疗的一个有问题的副作用。体重增加可以通过坚持饮食和运动或二甲双胍联合治疗来减轻或预防。体重增加在精神治疗中也很常见。非典型抗精神病药物(氯氮平、奥氮平、利培酮和喹硫平)已知会导致明显的体重增加。抗抑郁药如阿米替林、米氮平和一些血清素再摄取抑制剂(SSRIs)也可能促进明显的体重增加,这不能仅仅用抑郁症状的改善来解释。锂、丙戊酸和卡马西平等情绪稳定剂也会出现同样的现象。促进体重增加的抗癫痫药物包括丙戊酸盐、卡马西平和加巴喷丁。拉莫三嗪是一种体重中性的AED,而托吡酯和唑尼沙胺可能导致体重减轻。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
2nd international conference on hypertension, lipids, diabetes and stroke prevention. Web-based medical symposia. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Current challenges and directions in antithrombotic therapy. Myocardial infarction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1